Advanced searches left 3/3

Multiple Myeloma - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 13 May 2022

* If you want to update the article please login/register

The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma

With simultaneous research of HRQOL, the new strategy seeks to determine the sensitivity of immune function analysis for TCE intervention in MM patients undergoing ASCT.

Source link: https://clinicaltrials.gov/ct2/show/NCT04760405


Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma

Patients with newly diagnosed/suspected myeloma are unlikely to undergo or do not tolerate whole body MRI. Patients must remain within a narrow bore scanner with multiple MRI coils that can be claustrophobic. Patients will experience bone pain or fracture at some point during their illness, and it will influence their confidence within the scanner. In myeloma patients, the investigators believe that using a novel CT method, which is dual-energy CT, may produce improved diagnostic results over traditional WB-CT. The investigators want to assess the specificity of DECT in a cohort of untreated patients; also compare the results of DECT to simulated standard CT and then to a WB-MRI reference standard alongside bone marrow biopsy findings. The investigators will investigate both subjective visual interpretation of DECT images and CT quantitative measures for bone marrow.

Source link: https://clinicaltrials.gov/ct2/show/NCT05353907


Evaluating Study of Clinical Treatment of Multiple Myeloma Based on Analytical Omics

When using standard therapy, doctors discovered that different patients may have different clinical stability and adverse reactions. Gene and metabolic abnormalities in patients with multiple myeloma may be a significant factor influencing clinical success, according to several studies. In peripheral blood samples, it is predicted to find biomarkers and genes related to clinical safety, adverse reactions, and blood traces of bortezomib. Through the above studies, the project team hopes to develop a prediction model for the efficacy and safety of bortezomib-containing therapy for multiple myeloma patients.

Source link: https://clinicaltrials.gov/ct2/show/NCT04678089


A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma

This trial will determine whether it is a safe treatment for multiple myeloma and what side effects may occur. By itself, participants in Parts A and B of the SEA-BCMA. Participants will get SEA-BCMA and dexamethasone in Part C of the study. Both drugs, Dexamethasone and pomalidomide, can be used to treat multiple myeloma.

Source link: https://clinicaltrials.gov/ct2/show/NCT03582033


Comparison of 68Ga-pentixather and 68Ga-pentixafor PET/CT in Patients With Multiple Myeloma

Multiple myeloma is a malignant plasma cell disorder that is characterized by clonal proliferation of plasma cells in bone marrow microenvironment. However, an exchange of Ga3+ ions by other M3+ ions would result in a significant decrease in CXCR4 affinity, both diagnostic and therapeutic. In order to compare 68Ga-pentixather and 177Lu/90Y-pentixather in theranostics of MM, investigators conducted this prospective study to evaluate the diagnostic results of 68Ga-pentixather and 68Ga-pentixather.

Source link: https://clinicaltrials.gov/ct2/show/NCT05364177


A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

An expansion cohort of 14 patients will be treated at the recommended dose to establish treatment tolerance and evaluate evidence of treatment effectiveness.

Source link: https://clinicaltrials.gov/ct2/show/NCT03288480


Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma

Multiple myeloma is an asymptomatic disease with a 10-percent risk of progression to the incurable disease multiple myeloma each year. While many patients live for many years without advancement, high risk patients have a median risk of progression of 29 months. Since vaccines are generally low in terms of side effects, an efficient peptide vaccine would be the most suitable candidate. This report will determine if vaccination against the immune checkpoint molecule PD-L1 leads to responses in patients with elevated risk smoldering myeloma.

Source link: https://clinicaltrials.gov/ct2/show/NCT03850522


A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma

This is a controlled, open-label, multicenter research of daratumab in participants with intermediate or high risk Smoldering Multiple Myeloma. The study will include a 28-Day Screening Phase, a Treatment Phase of 1 to 20 cycle cycles, and a Follow-up Phase of 4-weeks from the last dose of study medication. The possibility of prolonging therapy with IV daratumumab after the conclusion of Cycle 20 is explored by the investigators, as per investigator discretion, a positive benefit-risk ratio, the absence of Grade >=3 treatment-related toxicity, and at least stable disease has been identified, has existed. The end of the study will take place about 7 years after the last participant enrolled receives the first dose of study medication.

Source link: https://clinicaltrials.gov/ct2/show/NCT02316106


A Phase II Study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma

Neuropathy is one of the side effects that can be present in some patients who receive thalidomide and/or bortezomib. Participants in the two groups will receive standard training from the academic researchers on the signs and symptoms of neuropathy. You will take a placebo once on Day 1 if you are tagged to Group A. On the day you start therapy with this research, you will take a greater dose of minocycline by mouth, and then a smaller dose of minocycline by mouth every 12 hours for ten weeks. If there is any serious concern about your health as a result of the drugs you might be taking, your physician will be advised which medications you are taking. The following tests and procedures will be done before starting each new cycle of multiple myeloma therapy for ten weeks: You will have a physical examination. If you're looking for unique sensations in your arms, legs, hands, and feet, or foot issues, you'll solve. After completing the study findings after Week 10, you will be asked to return for an end-of-study visit: You will need a physical exam. You will finish the questionnaire that includes questions about unusual sensations in your arms, legs, hands, and feet, as well as questions that may cause for you. Minocycline is not FDA-approved for use of neuropathy treatment.

Source link: https://clinicaltrials.gov/ct2/show/NCT01283997


Phase II Single Arm Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma

According to the International Myeloma Working Group Criteria, it is difficult to determine the rate of response. To determine the medical benefit rate, it's easiest to determine the medical benefit rate. In this population, there is no evidence of single agent therapy. OUTLINE: Patients receive isatuximab intravenously over 5 hours on day 1 of cycle 1 and over three hours later on days 8, 15, and 22, respectively on days 1 and 2 of cycle 1, and on day 1 of subsequent cycles, patients receive isatuximab intravenously over 5 hours.

Source link: https://clinicaltrials.gov/ct2/show/NCT02960555

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions